AMPH earnings

RANCHO CUCAMONGA, CA / ACCESSWIRE / January 8, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jack Zhang, CEO and President, and Bill Peters, CFO will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15th, 2025, at 11:15 am PST. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.About Amphastar:Amphastar is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Comp

RANCHO CUCAMONGA, CA / ACCESSWIRE / November 26, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Dan Dischner SVP of Corp. Communication, will participate in an Analyst-Moderated fireside chat at the 36th Annual Piper Sandler Healthcare Conference on Wednesday, December 4th, 2024 at 11:30 am EST. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.About Amphastar:Amphastar is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalatio

RANCHO CUCAMONGA, CA / ACCESSWIRE / November 13, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration, will participate in an Analyst-Moderated fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024 at 3:30 pm GMT. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.About Amphastar:Amphastar is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalatio

Reports Net Revenues of $191.2 Million for the Three Months Ended September 30, 2024RANCHO CUCAMONGA, CA / ACCESSWIRE / November 6, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the three months ended September 30, 2024.Third quarter HighlightsNet revenues of $191.2 million for the third quarterGAAP net income of $40.4 million, or $0.78 per share, for the third quarterAdjusted non-GAAP net income of $49.6 million, or $0.96 per share, for the third quarterDr. Jack Zhang, Amphastar's President and Chief Executive Officer, commented: "Amphastar has continued its growth this quarter, highlighted by sales, particularly from BAQSIMI®

RANCHO CUCAMONGA, CA / ACCESSWIRE / October 29, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its third quarter of 2024 ended September 30, 2024, after the market closes on Wednesday, November 6, 2024, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.To access the conference call, dial toll free 877-407-0989, for international calls, dial 201-389-0921, ten minutes before the conference.The call can also be accessed on the Investors page on the Company's website www.amphastar.com. The webcast replay of the call will be available on our Company website within 24 hours after the end of the live

RANCHO CUCAMONGA, CA / ACCESSWIRE / August 28, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, will participate in a fireside chat at the 2024 Wells Fargo Healthcare Conference on Thursday, September 5, 2024 at 10:15 am EST. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.About Amphastar:Amphastar is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and int

Reports Net Revenues of $182.4 Million for the Three Months Ended June 30, 2024RANCHO CUCAMONGA, CA / ACCESSWIRE / August 7, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the three months ended June 30, 2024.Second Quarter HighlightsNet revenues of $182.4 million for the second quarterGAAP net income of $37.9 million, or $0.73 per share, for the second quarterAdjusted non-GAAP net income of $48.7 million, or $0.94 per share, for the second quarterDr. Jack Zhang, Amphastar's President and Chief Executive Officer, commented: "As we finish another strong quarter, Amphastar has continued its impressive performance with solid sales

RANCHO CUCAMONGA, CA / ACCESSWIRE / July 31, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its Second quarter of 2024 ended June 30, 2024, after the market closes on Wednesday, August 7, 2024, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.To access the conference call, dial toll free 877-407-0989, for international calls, dial 201-389-0921, ten minutes before the conference.The call can also be accessed on the Investors page on the Company's website www.amphastar.com. The webcast replay of the call will be available on our Company website within 24 hours after the end of the live conferenc

RANCHO CUCAMONGA, CA / ACCESSWIRE / June 3, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration, will participate in an Analyst-Moderated fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 12:30 pm EST. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.About Amphastar:Amphastar is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and int

RANCHO CUCAMONGA, CA / ACCESSWIRE / May 9, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Dan Dischner SVP of Corp. Communication, will participate in an Analyst-Moderated fireside chat at the Bank of America Health Care Conference on Wednesday, May 15th, 2024 at 2:20 pm PDT. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.About Amphastar:Amphastar is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal pr

Reports Net Revenues of $171.8 Million for the Three Months Ended March 31, 2024 RANCHO CUCAMONGA, CA / ACCESSWIRE / May 8, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the three months ended March 31, 2024.First Quarter HighlightsNet revenues of $171.8 million for the first quarterGAAP net income of $43.2 million, or $0.81 per share, for the first quarterAdjusted non-GAAP net income of $55.3 million, or $1.04 per share, for the first quarterDr. Jack Zhang, Amphastar's President and Chief Executive Officer, commented: "Amphastar's strong first quarter results were led by BAQSIMI ® revenue growth of 22% over what Eli Lilly & Co

RANCHO CUCAMONGA, CA / ACCESSWIRE / April 30, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its first quarter of 2024 ended March 31, 2024, after the market closes on Wednesday, May 8, 2024, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.To access the conference call, dial toll free 877-407-0989, for international calls, dial 201-389-0921, ten minutes before the conference.The call can also be accessed on the Investors page on the Company's website www.amphastar.com. The webcast replay of the call will be available on our Company website within 24 hours after the end of the live conference

Reports Net Revenues of $178.1 Million for the Three Months Ended December 31, 2023RANCHO CUCAMONGA, CA / ACCESSWIRE / February 28, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the three months and full-year ended December 31, 2023.Fourth Quarter HighlightsNet revenues of $178.1 million for the fourth quarterGAAP net income of $36.2 million, or $0.68 per share, for the fourth quarterAdjusted non-GAAP net income of $46.9 million, or $0.88 per share, for the fourth quarterFull-Year HighlightsNet revenues of $644.4 million for the fiscal yearGAAP net income of $137.5 million, or $2.60 per share, for the fiscal yearAdjusted non-GA

RANCHO CUCAMONGA, CA / ACCESSWIRE / February 20, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its fourth quarter of 2023 ended December 31, 2023, after the market closes on Wednesday, February 28, 2024, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.To access the conference call, dial toll free 877-407-0989, for international calls, dial 201-389-0921, ten minutes before the conference.The call can also be accessed on the Investors page on the Company's website www.amphastar.com. The webcast replay of the call will be available on our Company website within 24 hours after the end of the liv

Reports Net Revenues of $180.6 Million for the Three Months Ended September 30, 2023RANCHO CUCAMONGA, CA / ACCESSWIRE / November 8, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the three months ended September 30, 2023.Third Quarter HighlightsNet revenues of $180.6 million for the third quarterGAAP net income of $49.2 million, or $0.91 per share, for the third quarterAdjusted non-GAAP net income of $61.9 million, or $1.15 per share, for the third quarterDr. Jack Zhang, Amphastar's President and Chief Executive Officer, commented: "We are pleased to announce strong results driven by the success of our diabetes portfolio, partic

RANCHO CUCAMONGA, CA / ACCESSWIRE / November 1, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its third quarter of 2023 ended September 30, 2023, after the market closes on Wednesday, November 8, 2023, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.To access the conference call, dial toll free 877-407-0989, for international calls, dial 201-389-0921, ten minutes before the conference.The call can also be accessed on the Investors page on the Company's website www.amphastar.com. The webcast replay of the call will be available on our Company website within 24 hours after the end of the live

RANCHO CUCAMONGA, CA / ACCESSWIRE / August 31, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, will participate in an Analyst-Moderated fireside chat at the Wells Fargo Healthcare Conference on September 7, 2023 at 12:45 pm Eastern Time. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com . This webcast will be available for 90 days following the presentation.About Amphastar:Amphastar is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhala

Reports Net Revenues of $145.7 Million for the Three Months Ended June 30, 2023RANCHO CUCAMONGA, CA / ACCESSWIRE / August 8, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the three months ended June 30, 2023.Second Quarter HighlightsNet revenues of $145.7 million for the second quarterGAAP net income of $26.1 million, or $0.49 per share, for the second quarterAdjusted non-GAAP net income of $34.8 million, or $0.65 per share, for the second quarterDr. Jack Zhang, Amphastar's President and Chief Executive Officer, commented: "We are pleased with the second quarter's results, which are partially attributable to glucagon and phyton

RANCHO CUCAMONGA, CA / ACCESSWIRE / August 2, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its second quarter of 2023 ended June 30, 2023, after the market closes on Tuesday, August 8, 2023, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.To access the conference call, dial toll free 877-407-0989, for international calls, dial 201-389-0921, ten minutes before the conference.The call can also be accessed on the Investors page on the Company's website www.amphastar.com.Company InformationAmphastar is a bio-pharmaceutical company that focuses primarily on developing, manufacturing, marketing,

RANCHO CUCAMONGA, CA / ACCESSWIRE / May 31, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Dan Dischner SVP of Corp. Communication, will participate in an Analyst-Moderated fireside chat at the Jefferies Healthcare Conference on June 8, 2023 at 2:30 pm Eastern Time. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com . This webcast will be available for 90 days following the presentation.About Amphastar:Amphastar is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. Ad

Reports Net Revenues of $140.0 Million for the Three Months Ended March 31, 2023RANCHO CUCAMONGA, CA / ACCESSWIRE / May 9, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the three months ended March 31, 2023.First Quarter HighlightsNet revenues of $140.0 million for the first quarterGAAP net income of $26.0 million, or $0.50 per share, for the first quarterAdjusted non-GAAP net income of $32.1 million, or $0.62 per share, for the first quarterDr. Jack Zhang, Amphastar's President and Chief Executive Officer, commented: "Strong sales of glucagon, Primatene MIST®, and epinephrine played a key role in driving our quarterly sales gr

RANCHO CUCAMONGA, CA / ACCESSWIRE / May 3, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its first quarter of 2023 ended March 31, 2023, after the market closes on Tuesday, May 9, 2023, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.To access the conference call, dial toll free (888) 645-4404, for international calls, dial (862) 298-0702, ten minutes before the conference.The call can also be accessed on the Investors page on the Company's website www.amphastar.com.Company InformationAmphastar is a bio-pharmaceutical company that focuses primarily on developing, manufacturing, marketing, an

Lilly focused on delivering the company's unprecedented pipeline of next-generation medicines to help patients Amphastar is the ideal company to continue Lilly's mission to help more people benefit from BAQSIMI INDIANAPOLIS and RANCHO CUCAMONGA, Calif., April 24, 2023 /PRNewswire/ -- In an effort to continue expanding the availability of BAQSIMI® to patients, Eli Lilly and Company (NYSE:LLY) and Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) have entered into a definitive agreement for Lilly to divest BAQSIMI worldwide to Amphastar, a global pharmaceutical company focused on developing, manufacturing, and marketing injectable, intranasal, and inhalation products including experience with a gl

RANCHO CUCAMONGA, CA / ACCESSWIRE / April 24, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will provide a Business update and hold a Conference call today, Monday, April 24, 2023, at 6:00 am Pacific Time.To access the conference call, please dial 877-407-0989, or for international callers, please dial +1 201-389-0921, five minutes before the conference begins.The live call and presentation can be accessed on the Amphastar Investors page at ir.amphastar.com or by using the webcast link below:https://www.webcast-eqs.com/amphastar_042423_en/enA replay of the call will also be available at the same link.Company InformationAmphastar is a bio-pharmaceutical compa

RANCHO CUCAMONGA, CA / ACCESSWIRE / April 12, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, Jacob Liawatidewi, EVP of Corporate Administration, Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, and Dan Dischner SVP of Corp. Communication, will participate in an Analyst-Moderated fireside chat at the 22nd Annual Needham Virtual Healthcare Conference on April 19th, 2023 at 12:45 pm Eastern Time. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com . This webcast will be available for 90 days following the presentation.About Amphastar:Amphastar is a biopharmaceutical company that focuses primarily on developi

RANCHO CUCAMONGA, CA / ACCESSWIRE / March 8, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") announced that the U.S. Food and Drug Administration ("FDA") has granted approval of its New Drug Application ("NDA") for naloxone hydrochloride nasal spray 4mg, which is delivered utilizing the Company's proprietary nasal delivery device. Naloxone hydrochloride nasal spray 4mg is indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression for adult and pediatric patients.Dr. Jack Zhang, Amphastar's President and Chief Executive Officer commented: "The approval of our naloxone hy

Reports Net Revenues of $135.0 Million for the Three Months Ended December 31, 2022RANCHO CUCAMONGA, CA / ACCESSWIRE / February 28, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the three months and full-year ended December 31, 2022.Fourth Quarter HighlightsNet revenues of $135.0 million for the fourth quarterGAAP net income of $33.9 million, or $0.66 per share, for the fourth quarterAdjusted non-GAAP net income of $37.6 million, or $0.73 per share, for the fourth quarterFull-Year HighlightsNet revenues of $499.0 million for the fiscal yearGAAP net income of $91.4 million, or $1.74 per share, for the fiscal yearAdjusted non-GAA

RANCHO CUCAMONGA, CA / ACCESSWIRE / February 22, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its fourth quarter of 2022 ended December 31, 2022, after the market closes on Tuesday, February 28, 2023, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.To access the conference call, dial toll free (877) 407-0989, for international calls, dial (201) 389-0921, five minutes before the conference.The call can also be accessed on the Investors page on the Company's website www.amphastar.com.Company InformationAmphastar is a bio-pharmaceutical company that focuses primarily on developing, manufacturi

RANCHO CUCAMONGA, CA / ACCESSWIRE / November 22, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Tony Marrs, Sr. Vice President Regulatory Affairs and Clinical Operations, will participate in an Analyst-Moderated fireside chat at the Piper Sandler 34th Annual Healthcare Conference on November 30th, 2022 at 11:00 am Eastern Time. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 90 days following the presentation.About Amphastar:Amphastar is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and p

RANCHO CUCAMONGA, CA / ACCESSWIRE / November 10, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Jacob Liawatidewi, Executive V.P. of Corporate Administration Center, will participate in an Analyst-Moderated fireside chat at the 2022 Jefferies London Healthcare Conference on November 16th , 2022 at 3:50 pm Greenwich Mean Time. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com . This webcast will be available for 90 days following the presentation.About Amphastar:Amphastar is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and pr

Reports Net Revenues of $120.1 Million for the Three Months Ended September 30, 2022RANCHO CUCAMONGA, CA / ACCESSWIRE / November 7, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the three months ended September 30, 2022.Third Quarter HighlightsNet revenues of $120.1 million for the third quarterGAAP net income of $15.9 million, or $0.30 per share, for the third quarterAdjusted non-GAAP net income of $20.2 million, or $0.38 per share, for the third quarterDr. Jack Zhang, Amphastar's President and Chief Executive Officer, commented: "We are pleased to report that our continued investment in capacity has successfully led to anothe

RANCHO CUCAMONGA, CA / ACCESSWIRE / October 28, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its third quarter of 2022 ended September 30, 2022, after the market closes on Monday, November 7, 2022, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.To access the conference call, dial toll free (877) 407-0989, for international calls, dial (201) 389-0921, five minutes before the conference.The call can also be accessed on the Investors page on the Company's website www.amphastar.com.Company InformationAmphastar is a bio-pharmaceutical company that focuses primarily on developing, manufacturing

RANCHO CUCAMONGA, CA / ACCESSWIRE / August 16, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's New Drug Application ("NDA") for Epinephrine injection USP, 1 mg/10mL (0.1 mg/mL) Single Dose Pre-Filled Syringe. Epinephrine injection is indicated to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock. For the past 30 years, the Company has sold and marketed Epinephrine injection under the "grandfather" exception to the FDA's "Prescription Drug Wrap-Up" program. Net revenues for the Company's Epinephrine injection for the year ended December 31, 2021, wer

Reports Net Revenues of $123.5 Million for the Three Months Ended June 30, 2022RANCHO CUCAMONGA, CA / ACCESSWIRE / August 8, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the three months ended June 30, 2022.Second Quarter HighlightsNet revenues of $123.5 million for the second quarterGAAP net income of $17.3 million, or $0.33 per share, for the second quarterAdjusted non-GAAP net income of $20.7 million, or $0.39 per share, for the second quarterDr. Jack Zhang, Amphastar's President and Chief Executive Officer, commented: "We've maintained momentum through the first half of 2022. Sales remained strong through the second quarte

RANCHO CUCAMONGA, CA / ACCESSWIRE / August 1, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its second quarter of 2022 ended June 30, 2022, after the market closes on Monday, August 8, 2022, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.To access the conference call, dial toll free (877) 407-0989, for international calls, dial (201) 389-0921, five minutes before the conference.The call can also be accessed on the Investors page on the Company's website www.amphastar.com.Company InformationAmphastar is a bio-pharmaceutical company that focuses primarily on developing, manufacturing, marketi

RANCHO CUCAMONGA, CA / ACCESSWIRE / May 24, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's Abbreviated New Drug Application ("ANDA") for Regadenoson injection, 0.08 mg/mL, 5mL Single Dose Pre-Filled Syringe. Regadenoson is indicated for radionuclide myocardial perfusion imaging (MPI) in patients unable to undergo adequate exercise stress. The FDA determined that Amphastar's regadenoson is bioequivalent and therapeutically equivalent to Astellas Pharma U.S., Inc's Lexiscan® (Regadenoson Injection).Amphastar's CEO and President, Dr. Jack Zhang, commented: "We are excited with the FDA's approval of our

Reports Net Revenues of $120.4 Million for the Three Months Ended March 31, 2022RANCHO CUCAMONGA, CA / ACCESSWIRE / May 9, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the three months ended March 31, 2022.First Quarter HighlightsNet revenues of $120.4 million for the first quarterGAAP net income of $24.3 million, or $0.47 per share, for the first quarterAdjusted non-GAAP net income of $24.6 million, or $0.47 per share, for the first quarterDr. Jack Zhang, Amphastar's President and Chief Executive Officer, commented: "The first quarter continued where 2021 ended, with strong sales of our recently launched products, which confi

RANCHO CUCAMONGA, CA / ACCESSWIRE / May 2, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its first quarter of 2022 ended March 31, 2022, after the market closes on Monday, May 9th 2022, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.To access the conference call, dial toll free (877) 407-0989, for international calls, dial (201) 389-0921, five minutes before the conference.The call can also be accessed on the Investors page on the Company's website www.amphastar.com.Company InformationAmphastar is a bio-pharmaceutical company that focuses primarily on developing, manufacturing, marketing, a

RANCHO CUCAMONGA, CA / ACCESSWIRE / April 8, 2022 / Amphastar Pharmaceuticals, Inc., (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's Abbreviated New Drug Application ("ANDA") for Ganirelix Acetate Injection, 250mg/0.5mL in a prefilled syringe. Ganirelix acetate injection is indicated for the inhibition of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation. The FDA determined Amphastar's ganirelix is bioequivalent and therapeutically equivalent to Organon Pharmaceuticals' Ganirelix Acetate Injection.Amphastar's CEO and President, Dr. Jack Zhang, commented: "We are excited about the FDA approva

Reports Net Revenues of $120.9 Million for the Three Months Ended December 31, 2021RANCHO CUCAMONGA, CA / ACCESSWIRE / March 10, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the three months and full-year ended December 31, 2021.Fourth Quarter HighlightsNet revenues of $120.9 million for the fourth quarterGAAP net income of $19.8 million, or $0.39 per share, for the fourth quarterAdjusted non-GAAP net income of $20.8 million, or $0.42 per share, for the fourth quarterFull-Year HighlightsNet revenues of $437.8 million for the fiscal yearGAAP net income of $62.1 million, or $1.25 per share, for the fiscal yearAdjusted non-GAAP n

RANCHO CUCAMONGA, CA / ACCESSWIRE / March 3, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its fourth quarter of 2021 ended December 31, 2021, after the market closes on Thursday, March 10th, 2022, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.To access the conference call, dial toll free (877) 407-0989, for international calls, dial (201) 389-0921, five minutes before the conference.The call can also be accessed on the Investors page on the Company's website www.amphastar.com.Company InformationAmphastar is a bio-pharmaceutical company that focuses primarily on developing, manufacturing,

RANCHO CUCAMONGA, CA / ACCESSWIRE / December 29, 2021 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has tentatively approved the Company's Abbreviated New Drug Application ("ANDA") for Vasopressin injection, USP 20 Units/mL, 1mL Single Dose Vial. Vasopressin is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. The FDA determined that Amphastar's vasopressin is bioequivalent and therapeutically equivalent to Par Sterile Products LLC's VASOSTRICT® (Vasopressin Injection, USP).Amphastar's CEO and President, Dr. Jack Zhang, commented: "The FDA's approval o

Reports Net Revenues of $112.2 Million for the Three Months Ended September 30, 2021RANCHO CUCAMONGA, CA / ACCESSWIRE / November 8, 2021 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the three months ended September 30, 2021.Third Quarter HighlightsNet revenues of $112.2 million for the third quarterGAAP net income of $29.5 million, or $0.59 per share, for the third quarterAdjusted non-GAAP net income of $23.0 million, or $0.46 per share, for the third quarterDr. Jack Zhang, Amphastar's President and Chief Executive Officer, commented: "We delivered record sales due to the continued momentum driven by the strength of our glucagon, P

RANCHO CUCAMONGA, CA / ACCESSWIRE / October 28, 2021 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its third quarter of 2021 ended September 30, 2021, after the market closes on Monday, November 8, 2021, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.To access the conference call, dial toll free (877) 407-0989, for international calls, dial (201) 389-0921, five minutes before the conference.The call can also be accessed on the Investors page on the Company's website www.amphastar.com.Company InformationAmphastar is a bio-pharmaceutical company that focuses primarily on developing, manufacturing,

Reports Net Revenues of $101.7 Million for the Three Months Ended June 30, 2021RANCHO CUCAMONGA, CA / ACCESSWIRE / August 9, 2021 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the three months ended June 30, 2021.Second Quarter HighlightsNet revenues of $101.7 million for the second quarterGAAP net income of $7.8 million, or $0.16 per share, for the second quarterAdjusted non-GAAP net income of $10.6 million, or $0.21 per share, for the second quarterDr. Jack Zhang, Amphastar's President and Chief Executive Officer, commented: "Continued strong sales of glucagon, Primatene Mist® and our epinephrine products led to another strong qua

RANCHO CUCAMONGA, CA / ACCESSWIRE / July 29, 2021 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its second quarter of 2021 ended June 30, 2021, after the market closes on Monday, August 9th, 2021, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.To access the conference call, dial toll free (877) 407-0989, for international calls, dial (201) 389-0921, five minutes before the conference.The call can also be accessed on the Investors page on the Company's website www.amphastar.com.Amphastar is a specialty pharmaceutical company that primarily develops, manufactures, markets, and sells generic and pr

Reports Net Revenues of $103.0 Million for the Three Months Ended March 31, 2021 RANCHO CUCAMONGA, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the three months ended March 31, 2021. First Quarter Highlights Net revenues of $103.0 million for the first quarterGAAP net income of $5.0 million, or $0.10 per share, for the first quarterAdjusted non-GAAP net income of $13.6 million, or $0.27 per share, for the first quarter Dr. Jack Zhang, Amphastar's President and Chief Executive Officer commented: "The launch of glucagon, along with strong sales growth of Primatene Mist® and our epinephrine

RANCHO CUCAMONGA, Calif., March 15, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months and full-year ended December 31, 2020. Fourth Quarter Highlights Net revenues of $95.9 million for the fourth quarterGAAP net loss of $6.3 million, or $0.13 per share, for the fourth quarterAdjusted non-GAAP net income of $8.0 million, or $0.16 per share, for the fourth quarter Full-Year Highlights Net revenues of $349.8 million for the fiscal yearGAAP net income of $1.4 million, or $0.03 per share, for the fiscal yearAdjusted non-GAAP net income of $31.6 million, or $0.64 per share, for th